Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

PurposeImmune-mediated adverse events (imAEs) may be associated with response to immune checkpoint inhibitors. We assessed the relationship between imAE development and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab (anti-programmed cell death ligand-1 [PD-L1]) al...

Full description

Bibliographic Details
Main Authors: Agnish Dey, Matthew Austin, Harriet M. Kluger, Nataliya Trunova, Helen Mann, Norah Shire, Claire Morgan, Diansong Zhou, Ganesh M. Mugundu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
immunology
biomarkers
clinical trials
methodology and modeling
immunotherapy
computational methods
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1026964/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1026964/full

Similar Items